PBYI Stock Analysis: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$8.26
0.27 (3.38%)
▲
5d:
+7.69%
30d:
+18.34%
90d:
+22.19%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PBYI shows positive signals but monitor for confirmation. Market pricing in 20.9% growth. Moderate conviction.
💡 BUY OPPORTUNITY: PBYI shows positive signals but monitor for confirmation. Market pricing in 20.9% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.81
Based on -9.1% avg growth
INTRINSIC VALUE TODAY
$1.75
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $8.26, which is considered extended relative to its 30-day fair value range of $6.98 to $7.87. From a valuation perspective, the stock is trading at a premium (Forward PE: 23.6) compared to its historical average (13.3). At these levels, the market is pricing in 20.9% annual earnings growth.
Technical Outlook: Technically, PBYI is in a uptrend. The price is approaching resistance at $7.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: PBYI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PBYI is in a uptrend. The price is approaching resistance at $7.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: PBYI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.98 -
$7.87
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BEARISH: Trading 39.5% above Wall St target ($5.00)
- BULLISH: Expecting earnings turnaround to 20.9% growth with -2.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$6.98 -
$7.87
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.99
(11.9%)
Support & Resistance Levels
Support Level
$6.78
Resistance Level
$7.45
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.60
Wall Street Target
$5.00
(-39.5%)
Revenue Growth (YoY)
-2.6%
Earnings Growth (YoY)
-34.4%
Profit Margin
10.7%
Valuation Premium vs History
+20.9% premium
PE vs Historical
23.6 vs 13.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+20.9%
(market-implied from PE analysis)
1-Year Target
$9.99
(+21%)
2-Year Target
$12.07
(+46%)
3-Year Target
$14.60
(+77%)
3-Yr Target (if PE normalizes)
(PE: 24→13)
PE COMPRESSION
$8.23
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.6, Growth: -22.2%)
$6.02
(+-27%)
Base:
(SPY PE: 21.8, Growth: -22.2%)
$5.56
(-33%)
Bear:
(PE: 13.3, Growth: -22.2%)
$3.39
(-59%)
📈
Valuation based on Current Earnings
Trailing PE: 16.65 | Current EPS (TTM): $0.48
Bull Case
$6.41
(-22%)
Analyst growth -27.1%, PE expands to 18.3
Base Case
$5.83
(-30%)
Market implied -27.1%, PE stable at 16.7
Bear Case
$5.43
(-34%)
Severe decline -20.0%, PE contracts to 14.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 5:09 PM ET
Data refreshes hourly during market hours. Next update: 6:09 PM
Data refreshes hourly during market hours. Next update: 6:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan H Auerbach
SELL
18012 shares
2026-01-07
Douglas M Hunt
SELL
5014 shares
2026-01-07
Alan H Auerbach
SELL
16938 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
